Pharmaceutical Analysis & Statistics in Oceania Countries, May 2013 (p10)

271-320 of about 500 reports

Purchase Reports From Reputable Market Research Publishers

Flovent (Asthma) - Forecast and Market Analysis to 2023

Flovent (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flovent (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flovent (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Pulmicort (Asthma) - Forecast and Market Analysis to 2023

Pulmicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Pulmicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Pulmicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Advair (Asthma) - Forecast and Market Analysis to 2023

Advair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Advair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Advair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Symbicort (Asthma) - Forecast and Market Analysis to 2023

Symbicort (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Symbicort (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Symbicort (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Breo Ellipta (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : World, Australia, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom
Flutiform (Asthma) - Forecast and Market Analysis to 2023

Flutiform (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Flutiform (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Flutiform (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United Kingdom, Europe
Singulair (Asthma) - Forecast and Market Analysis to 2023

Singulair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Singulair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Singulair (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Drug and Medication
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Xolair (Asthma) - Forecast and Market Analysis to 2023

Xolair (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Xolair (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Xolair (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Spiriva (Asthma) - Forecast and Market Analysis to 2023

Spiriva (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Spiriva (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Spiriva (Asthma) - Forecast and Market Analysis to 2023”. The asthma ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Fluticasone Furoate (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Fluticasone Furoate (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Japan, Australia, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe
Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Cinquil (Reslizumab) (Asthma) - Forecast and Market Analysis ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Bosatria (Mepolizumab) (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Bosatria (Mepolizumab) (Asthma) - Forecast and Market ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lebrikizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Benralizumab (Asthma) - Forecast and Market Analysis to 2023

Benralizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Benralizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Benralizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Dupilumab (Asthma) - Forecast and Market Analysis to 2023

Dupilumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Dupilumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Dupilumab (Asthma) - Forecast and Market Analysis to 2023”. The ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Quilizumab (Asthma) - Forecast and Market Analysis to 2023

Quilizumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Quilizumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Quilizumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • August 2014
  • by Global Data

Tralokinumab (Asthma) - Forecast and Market Analysis to 2023 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tralokinumab (Asthma) - Forecast and Market Analysis to 2023”. ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe
Australia Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

Australia Pharmaceuticals and Healthcare Industry Update Quarter 4 2011

  • $ 1 300
  • Industry report
  • August 2014
  • by Business Monitor International

BMI View: Australian prospects for multinational drugmakers are mixed. In the first quarter of the year it was announced that eight medicines would not be included in the country's Pharmaceutical Benefits ...

  • Industries : Drug and Medication
  • Countries : Australia
Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM

  • $ 4 995
  • Industry report
  • August 2014
  • by GBI Research

Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM Summary GBI Research, the leading business ...

  • Industries : Therapy
  • Countries : Australia, India, Japan, China, World, United States, Asia, Oceania
Bioject Medical Technologies Inc. (Symbol:BJCT) SWOT Analysis, Strategy, Revenues and Profits

Bioject Medical Technologies Inc. (Symbol:BJCT) SWOT Analysis, Strategy, Revenues and Profits

  • $ 125
  • Company report
  • August 2014
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Drug Delivery Technology
  • Countries : Australia, World, Ecuador, China
Australia Hernia Repair Market Outlook to 2020

Australia Hernia Repair Market Outlook to 2020

  • $ 2 500
  • Industry report
  • July 2014
  • by Global Data

Australia Hernia Repair Market Outlook to 2020 Summary GlobalData's new report, "Australia Hernia Repair Market Outlook to 2020", provides key market data on the Australia Hernia Repair market. The report ...

  • Industries : Pathology
  • Countries : Australia
Asia-Pacific Hernia Repair Market Outlook to 2020

Asia-Pacific Hernia Repair Market Outlook to 2020

  • $ 3 000
  • Industry report
  • July 2014
  • by Global Data

Asia-Pacific Hernia Repair Market Outlook to 2020 Summary GlobalData's new report, "Asia-Pacific Hernia Repair Market Outlook to 2020", provides key market data on the Asia-Pacific Hernia Repair market. ...

  • Industries : Pathology
  • Countries : South Korea, Australia, Japan, India, China, Asia, World, Oceania
Australia Hernia Repair Procedures Outlook to 2020

Australia Hernia Repair Procedures Outlook to 2020

  • $ 175
  • Industry report
  • July 2014
  • by Global Data

Australia Hernia Repair Procedures Outlook to 2020 Summary GlobalData's new report, "Australia Hernia Repair Procedures Outlook to 2020", provides key market data on the Australia Hernia Repair Procedures. ...

  • Industries : Pathology
  • Countries : Australia
Asia-Pacific Hernia Repair Procedures Outlook to 2020

Asia-Pacific Hernia Repair Procedures Outlook to 2020

  • $ 450
  • Industry report
  • July 2014
  • by Global Data

Asia-Pacific Hernia Repair Procedures Outlook to 2020 Summary GlobalData's new report, "Asia-Pacific Hernia Repair Procedures Outlook to 2020", provides key market data on the Asia-Pacific Hernia Repai ...

  • Industries : Pathology
  • Countries : South Korea, Australia, China, India, Japan, Asia, World, Oceania
Dimerix Bioscience Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Dimerix Bioscience Pty Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

Summary Dimerix Bioscience Pty Ltd (Dimerix) is a biopharmaceutical company. The company offers drug discovery assays and progressing clinical programs. Its heteromer identification technology assay is ...

  • Industries : Pharmaceutical
  • Countries : Australia
Edmond Pharma Srl - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Edmond Pharma Srl - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

Summary Edmond Pharma Srl (Edmond Pharma) is a pharmaceutical company. The company manufactures active ingredients, finished products, and pharmaceutical specialties. It operates through two divisions ...

  • Industries : Drug and Medication
  • Countries : Australia
DSM Biologics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

DSM Biologics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

Summary DSM Biologics, Inc. (DSM Biologics) is a privately held canadian based pharmaceutical company. It is a subsidiary of DSM Pharmaceutical Products. The company is engaged in manufacturing biological ...

  • Industries : Pharmaceutical
  • Countries : Canada, Australia, Netherlands, North America, World
Helsinn Healthcare S.A. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Helsinn Healthcare S.A. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

Summary Helsinn Healthcare S.A. (Helsinn Healthcare) is a specialty pharmaceutical company. It focuses on the in-licensing, development, manufacture and commercialization of drugs. The company specialize ...

  • Industries : Pharmaceutical
  • Countries : Australia
EffRx Pharmaceuticals S.A. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

EffRx Pharmaceuticals S.A. - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

Summary EffRx Pharmaceuticals S.A. (EffRx) formerly EffRx, Inc. is a pharmaceutical company. The company offers medications for metabolic bone disease, oncology supportive care, and pediatric conditions. ...

  • Industries : Pharmaceutical
  • Countries : World, Australia, Switzerland
ChemGenex Pharmaceuticals Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

ChemGenex Pharmaceuticals Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • July 2014
  • by Global Data

Summary ChemGenex Pharmaceuticals Limited (ChemGenex Pharmaceuticals) is an Australia based genomics-driven pharmaceutical development company dedicated to improving the lives of patients by developing ...

  • Industries : Pharmaceutical
  • Countries : Australia

1 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.